MedPath

Adjuvant Effect of Dexmedetomidine in Ultrasound (USG) Guided Transvers Abdominis Plane Block

Phase 3
Withdrawn
Conditions
Postoperative Nausea and Vomiting
Interventions
Registration Number
NCT02331563
Lead Sponsor
Kırıkkale University
Brief Summary

A total of 60 adult patients American Society of Anesthesiologists physical status I,II, III were randomized to Group B (n = 30) receiving TAP block with 0.25% bupivacaine and Group D (n = 30) with 0.5 mcg/kg dexmedetomidine added to 0.25 % bupicavaine followed by general anaesthesia. Total local anaesthetic volume was standardised with 20 ml each sides of the abdomen. Hemodynamic responses to surgical incision and intraoperative fentanyl consumption were noted. Visual analog scale (VAS) scores were assessed on the emergence, at 1, 2, 3, 4, 5, 6 and 24 h. Time to first rescue analgesic (when VAS ≥4 cm or on demand), duration of postoperative analgesia, incidence of postoperative nausea-vomiting were also noted.

Detailed Description

Transversus abdominis plane (TAP) block has been shown to provide postoperative pain relief following various abdominal and inguinal surgeries. The aim of this randomised controlled trial was to assess the effect of transversus abdominis plane (TAP) blocks on opioid requirements and median hospitai stay, postoperative nause and vomitting in patients undergoing laparoscopic cholecystectomy.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • The patients undergoing laparascopic cholecystectomy
Exclusion Criteria
  • Story of allergy to bupivacaine and dexmedetomidine
  • The surgery preceeded to laparatomy
  • Recent abdominal operation history

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
0.5% bupivacaine0.25 % bupivacainegroup 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
dexmedetomidine added bupivacaineDexmedetomidinegroup II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
Primary Outcome Measures
NameTimeMethod
opioid requirement24 hr

postoperative relief

Secondary Outcome Measures
NameTimeMethod
postoperative nause and vomiting24 hrs

patient relief

Trial Locations

Locations (1)

Kırıkkale University School of Medicine Department of Anaesthesiology and Reanimation

🇹🇷

Kırıkkale, Yahşihan, Turkey

© Copyright 2025. All Rights Reserved by MedPath